Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...

TOS-358 is an oral, highly selective, pan-mutant, covalent PI3Ka inhibitor that achieves >95% continuous target engagement for deep and durable inhibition of PI3K-AKT signaling which is required for ...

Icotrokinra is a once-daily, empty-stomach oral peptide that antagonizes IL‑23R, aiming to match biologic pathway selectivity while overcoming historic oral peptide bioavailability barriers. Duplicate ...

The FDA clears 1st oral pill for plaque psoriasis, approving Johnson & Johnson’s Icotyde for adults and pediatric patients age 12 and older.

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 years and older.

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on ...